Skip to main content
. Author manuscript; available in PMC: 2016 Oct 31.
Published in final edited form as: Clin Infect Dis. 2015 Aug 30;62(1):90–98. doi: 10.1093/cid/civ708

Table 1.

Percentagea of Patients by Healthcare Payer Type: By Patient Characteristics, Medical Monitoring Project, 2009–2013 (n = 18 049)

Total Sample Healthcare Coverage 56.5% of Total (95% CI, 54.6–58.4) Healthcare Coverage + RWHAP Assistance 25.4% of Total (95% CI, 23.5–27.3) RWHAP Assistance Only 15.3% of Total (95% CI, 13.1–17.6) Uninsured, no RWHAP Assistance 2.7% of Total (95% CI, 2.1–3.3)
n % 95% CI % 95% CI % 95% CI % 95% CI % 95% CI
Healthcare payer type
 RWHAP only 2581 15.3 13.1 17.6 100.0
 Private 2882 17.0 14.8 19.1 30.0 26.6 33.7
 Medicaid 2905 15.9 14.3 17.6 28.2 25.3 31.1
 Medicare 634 3.4 2.9 3.8 5.9 5.2 6.8
 Medicaid + Medicare 1619 9.4 8.3 10.5 16.7 14.7 18.9
 Other public 446 1.6 .3 2.9 2.9 1.3 6.2
 Private + RWHAP 944 5.2 4.6 5.8 20.6 18.3 23.1
 Medicaid+RWHAP 1087 5.5 4.3 6.6 21.5 16.6 27.2
 Medicare+RWHAP 625 3.4 2.8 4.1 13.5 11.2 16.2
 Medicaid+Medicare+RWHAP 764 4.2 3.5 4.9 16.5 13.5 19.9
 Other public + RWHAP 539 2.5 1.4 3.5 9.7 6.6 13.8
 VA/Champus/Tricareb 353 1.8 1.0 2.7 3.0 1.9 4.9 .5 .3 .8
 Other payer typeb 2181 12.1 9.9 14.2 13.3 11.6 15.2 17.8 13.5 23.1
 Uninsured 489 2.7 2.1 3.3 100.0
Gender
 Male 13 025 72.4 70.0 74.8 70.3 67.5 73.1 76.0 72.6 79.4 74.8 72.5 77.1 68.2 63.4 73.0
 Female 4772 26.3 23.9 28.6 28.6 25.9 31.4 22.6 19.2 26.0 23.0 20.9 25.1 29.9 24.9 34.9
 Transgender/Intersex 246 1.3 1.1 1.6 1.1 .8 1.3 1.4 1.0 1.7 2.2 1.6 2.7 1.9 .6 3.2
Age (years)
 18–29 1336 7.6 6.8 8.3 5.6 4.9 6.3 6.9 5.6 8.2 14.1 12.3 15.9 18.3 13.4 23.2
 30–39 2834 16.0 15.3 16.7 13.6 12.9 14.4 15.3 13.9 16.6 23.6 21.8 25.4 28.8 23.9 33.6
 40–49 6380 35.1 34.3 35.9 34.7 33.5 35.8 35.1 33.4 36.8 37.1 35.1 39.2 32.4 27.4 37.4
 ≥50 7499 41.3 40.5 42.2 46.1 44.8 47.4 42.8 40.2 45.4 25.2 23.0 27.3 20.5 17.0 24.0
Race/Ethnicity
 non-Hispanic black 7457 41.3 34.7 48.0 41.4 34.6 48.2 36.7 27.7 45.8 46.5 41.2 51.9 53.7 47.1 60.4
 non-Hispanic white 5887 34.5 29.3 39.7 35.7 30.1 41.3 40.9 33.4 48.4 22.5 19.9 25.1 16.4 12.6 20.1
 Hispanic 3876 19.3 15.2 23.5 18.1 13.3 23.0 17.3 12.7 21.8 26.2 21.4 31.0 25.5 20.3 30.7
 Other 829 4.8 4.1 5.5 4.7 3.9 5.5 5.1 4.0 6.2 4.8 3.8 5.7 4.4 2.3 6.5
Nativity
 US-born 15 663 86.6 85.1 88.1 90.4 88.9 91.8 88.7 86.9 90.4 71.6 66.5 76.7 73.4 66.5 80.2
 Foreign-born 2379 13.4 11.9 14.9 9.6 8.2 11.1 11.3 9.6 13.1 28.4 23.3 33.5 26.6 19.8 33.5
Education
 Less than high school 3958 21.0 19.1 22.8 21.9 19.8 24.1 17.5 14.6 20.4 22.4 20.5 24.3 25.9 21.1 30.7
 High school graduatec 4924 27.0 25.4 28.6 25.8 24.3 27.2 26.7 24.1 29.3 31.1 28.7 33.5 32.3 27.9 36.7
 Some college or more 9160 52.0 48.9 55.2 52.3 49.0 55.6 55.8 50.8 60.9 46.5 43.8 49.2 41.9 36.7 47.0
Poverty statusd
 Above poverty level 9418 55.8 52.8 58.8 56.5 52.6 60.3 60.0 57.2 62.8 47.9 45.0 50.8 44.8 39.9 49.7
 At or below poverty level 8033 44.2 41.2 47.2 43.5 39.7 47.4 40.0 37.2 42.8 52.1 49.2 55.0 55.2 50.3 60.1
Homeless (past 12 mo)e
 Yes 1510 8.2 7.6 8.9 7.5 6.7 8.3 8.1 7.0 9.1 10.2 8.3 12.2 13.0 10.4 15.6
 No 16 538 91.8 91.1 92.4 92.5 91.7 93.3 91.9 90.9 93.0 89.8 87.8 91.7 87.0 84.4 89.6
Time since HIV diagnosis
 <5 y 3772 22.1 21.1 23.1 18.8 17.6 19.9 20.2 18.7 21.7 33.2 30.8 35.6 46.6 41.4 51.7
 5–9 y 3851 21.3 20.6 22.0 20.2 19.3 21.1 20.3 19.1 21.4 25.8 23.7 27.8 26.3 22.6 30.1
 10+ years 10 416 56.6 55.3 58.0 61.0 59.5 62.5 59.5 57.7 61.4 41.1 38.9 43.2 27.1 23.0 31.2
HIV disease stagef
 Stage 1: No AIDS and nadir CD4 ≥500 (or CD4% ≥29) 1203 7.0 6.5 7.5 7.3 6.6 7.9 5.7 4.7 6.6 6.6 5.5 7.6 15.7 11.9 19.6
 Stage 2: No AIDS and nadir CD4 200–499 (or CD4% 14–<29) 4310 24.4 23.5 25.3 23.7 22.4 24.9 20.3 18.4 22.2 31.0 28.9 33.0 39.5 34.2 44.8
 Stage 3: AIDS or nadir CD4 0–199 (or CD4% <14) 12 469 68.7 67.7 69.6 69.1 67.7 70.4 74.0 71.6 76.5 62.5 60.3 64.6 44.7 38.3 51.1
Prescribed ARTg (%)
 Yes 16 495 91.1 90.6 91.7 90.3 89.6 91.0 95.4 94.4 96.4 94.2 92.8 95.5 52.1 46.0 58.2
 No 1554 8.9 8.3 9.4 9.7 9.0 10.4 4.6 3.6 5.6 5.8 4.5 7.2 47.9 41.8 54.0
HIV viral load undetectable or <200 copies/mL (%)
 Yes
13 530 74.7 73.5 76.0 74.3 72.8 75.8 78.4 76.8 80.0 76.7 74.5 78.8 38.8 33.7 43.9
 No 4519 25.3 24.0 26.5 25.7 24.2 27.2 21.6 20.0 23.2 23.3 21.2 25.5 61.2 56.1 66.3
 Total 18 095 100.0 100.0 100.0 100.0 100.0

Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; RWHAP, Ryan White HIV/AIDS Program.

a

Percentages and 95% CIs are weighted to account for unequal selection probabilities and non-response.

b

Some patients with this payer type also received RWHAP assistance.

c

Includes general education development (GED) credential.

d

US Department of Health and Human Services. HHS Poverty Guidelines. Available at: http://aspe.hhs.gov/poverty/09poverty.shtml.

e

McKinney-Vento definition of homelessness: living on the street, living in a shelter, living in a single-room-occupancy hotel, temporarily staying with friends or family, or living in a car. A person is categorized as homeless if that person lacks a fixed, regular, adequate night-time residence or has a steady night-time residence that is 1) a supervised publicly or privately operated shelter designed to provide temporary living accommodation, 2) an institution that provides a temporary residence for persons intended to be institutionalized, or 3) a public or private place not designed for or ordinarily used as a regular sleeping accommodation for human beings (eg, in an automobile or under a bridge) (Stewart B. McKinney Homeless Assistance Act, 42 U.S.C. §11301, et seq; 1987).

f

Schneider E, Whitmore S, Glynn KM, et al Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years—United States, 2008. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports/Centers for Disease Control. Dec 5 2008; 57(RR-10):1–12.

g

Documented ART prescription in the medical record during the 12 months prior to interview.